<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="72202">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02165761</url>
  </required_header>
  <id_info>
    <org_study_id>HVG 13-01</org_study_id>
    <nct_id>NCT02165761</nct_id>
  </id_info>
  <brief_title>Evaluation of Anti-platelet Factor 4/Heparin Antibodies in Hemodialysis Patients</brief_title>
  <official_title>Evaluation of Anti-platelet Factor 4/Heparin Antibodies in Hemodialysis Patients Implanted With the GORE® Hybrid Vascular Graft Versus Non-heparin Bonded Synthetic Vascular Grafts.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>W.L.Gore &amp; Associates</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>W.L.Gore &amp; Associates</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To characterize the GORE® Hybrid Vascular Graft as compared to non-heparin bonded synthetic
      vascular grafts in terms of the prevalence and persistence of anti-platelet factor 4 /
      heparin antibodies (anti-PF4 / H antibodies).
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date>July 2014</start_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Prevalence of a positive poly-specific enzyme immunoassay (EIA) at Day 7 and/or Day 14 time points</measure>
    <time_frame>14 days</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>End Stage Renal Disease</condition>
  <arm_group>
    <arm_group_label>GORE® Hybrid Vascular Graft</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>GORE® Hybrid Vascular Graft</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-heparin bonded synthetic graft</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Non-heparin bonded synthetic graft</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>GORE® Hybrid Vascular Graft</intervention_name>
    <arm_group_label>GORE® Hybrid Vascular Graft</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Non-heparin bonded synthetic graft</intervention_name>
    <arm_group_label>Non-heparin bonded synthetic graft</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The patient is not a candidate for a native fistula.

          -  The patient requires the creation of an upper arm vascular access graft for
             hemodialysis secondary to a diagnosis of End-Stage Renal Disease.

          -  The patient has been on hemodialysis for ≥1 month.

        Exclusion Criteria:

          -  The patient is scheduled for a different surgical procedure within 30 days post Index
             Procedure.

          -  The patient has a known hypercoagulable disorder or bleeding disorder.

          -  The patient has had a previous instance of Heparin Induced Thrombocytopenia Type II
             (HIT type II) or has known sensitivity to heparin.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <lastchanged_date>April 26, 2016</lastchanged_date>
  <firstreceived_date>June 13, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hemodialysis</keyword>
  <keyword>End Stage Renal Disease</keyword>
  <keyword>Vascular Graft</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Heparin</mesh_term>
    <mesh_term>Platelet Factor 4</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
